Conference Coverage: BMT Tandem Meetings

Conference Coverage

Promising results with expanded UCB product

SALT LAKE CITY—An expanded umbilical cord blood (UCB) product can produce favorable outcomes as a stand-alone graft, according to a presentation...

Conference Coverage

Outcomes appear similar with MAC and RIC

SALT LAKE CITY—New research suggests outcomes may be similar whether patients receive ­myeloablative conditioning (MAC) or reduced-intensity...

Conference Coverage

Team identifies biomarkers for cGVHD in kids

SALT LAKE CITY—Researchers say they have identified prognostic biomarkers for chronic graft-vs-host disease (cGVHD) in children. The group found...

Conference Coverage

Expanded UCB product can stand alone

SALT LAKE CITY—The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the...

Conference Coverage

Regimen deemed ‘safe and feasible’ in MM

SALT LAKE CITY—A novel transplant regimen is “safe and feasible” for patients with multiple myeloma (MM), according to a presentation at the 2018...

Conference Coverage

Tocilizumab shows promise for GVHD prevention

ORLANDO – The interleuken-6 receptor blocker tocilizumab showed promising activity for preventing graft-versus-host disease when added to standard...

Pages